This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
IM Cannabis Corp. (IMCC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
IM Cannabis (IMCC) delivered earnings and revenue surprises of 79.76% and 12.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CareCloud, Inc. (CCLD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CareCloud (CCLD) delivered earnings and revenue surprises of 50% and 0.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Prestige Consumer Healthcare (PBH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 4.65% and 2.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Q2 Earnings Beat Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 150% and 2.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -26.32% and 0.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
IM Cannabis Corp. (IMCC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
IM Cannabis (IMCC) delivered earnings and revenue surprises of 0% and 14.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
IM Cannabis (IMCC) Expands Business in Germany With New Alliance
by Zacks Equity Research
The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.
Warby Parker Inc. (WRBY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Warby Parker Inc. (WRBY) delivered earnings and revenue surprises of 100% and 2.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Verano Holdings Corp. (VRNOF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of -100% and 1.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Beats Q2 Earnings Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 21.29% and 2.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 63.16% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -157.01% and 81.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.53% and 4.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zimmer Biomet (ZBH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 13.86% and 7.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.31% and 48.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Leafly Holdings, Inc. (LFLY) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Leafly Holdings, Inc. (LFLY) delivered earnings and revenue surprises of -6.25% and 0.68%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
IM Cannabis Corp. (IMCC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
IM Cannabis Corp. (IMCC) delivered earnings and revenue surprises of 16.67% and 45.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
OncoCyte (OCX) delivered earnings and revenue surprises of 38.46% and 32.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm (VAPO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vapotherm (VAPO) delivered earnings and revenue surprises of -16.88% and 19.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
IM Cannabis Corp. (IMCC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
IM Cannabis Corp. (IMCC) delivered earnings and revenue surprises of -700% and 8.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Senestech, Inc. (SNES) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Senestech, Inc. (SNES) delivered earnings and revenue surprises of -10.53% and 24.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 30.93% and 78.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Abbott (ABT): Can Its 3.1% Jump Turn into More Strength?
by Zacks Equity Research
Abbott (ABT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
IM Cannabis Corp. (IMCC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
IM Cannabis Corp. (IMCC) delivered earnings and revenue surprises of -550% and 6.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?